Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Colorcon
Julphar
Cipla
Teva
Citi
Johnson and Johnson
McKesson
Cantor Fitzgerald

Generated: December 17, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CRIZOTINIB

« Back to Dashboard

Clinical Trials for Crizotinib

Trial ID Title Status Sponsor Phase Summary
NCT00939770 Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Active, not recruiting National Cancer Institute (NCI) Phase 1/Phase 2 RATIONALE: Crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of crizotinib and to see how well it works in treating young patients with relapsed or refractory solid tumors or anaplastic large cell lymphoma.
NCT00939770 Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Active, not recruiting Children's Oncology Group Phase 1/Phase 2 RATIONALE: Crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of crizotinib and to see how well it works in treating young patients with relapsed or refractory solid tumors or anaplastic large cell lymphoma.
NCT01082380 Radiolabeled [14C]PF-02341066 Study To Investigate The Absorption, Metabolism And Excretion In Healthy Male Volunteers Completed Pfizer Phase 1 The rationale for this study is to investigate the absorption, metabolism and excretion of [14C]PF 02341066 and characterize plasma, fecal and urinary radioactivity, and identify any metabolites, if possible, of [14C]PF 02341066 in humans.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Crizotinib

Condition Name

Condition Name for Crizotinib
Intervention Trials
Non-Small Cell Lung Cancer 23
Healthy 10
Carcinoma, Non-Small-Cell Lung 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Crizotinib
Intervention Trials
Carcinoma, Non-Small-Cell Lung 52
Lung Neoplasms 45
Lymphoma 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Crizotinib

Trials by Country

Trials by Country for Crizotinib
Location Trials
United States 599
Italy 78
Japan 63
China 53
Spain 50
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Crizotinib
Location Trials
California 28
Texas 28
Florida 25
Massachusetts 24
Ohio 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Crizotinib

Clinical Trial Phase

Clinical Trial Phase for Crizotinib
Clinical Trial Phase Trials
Phase 4 3
Phase 3 14
Phase 2 48
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Crizotinib
Clinical Trial Phase Trials
Recruiting 52
Active, not recruiting 22
Not yet recruiting 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Crizotinib

Sponsor Name

Sponsor Name for Crizotinib
Sponsor Trials
Pfizer 44
National Cancer Institute (NCI) 11
Hoffmann-La Roche 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Crizotinib
Sponsor Trials
Other 112
Industry 90
NIH 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Argus Health
Julphar
Healthtrust
Moodys
US Department of Justice
Dow
Cantor Fitzgerald
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.